Over the last couple of years, prescribers have been inundated with new inhaled drug options for the management of chronic obstructive pulmonary disease (COPD). However, despite the introduction of new products there are still only three main classes of inhaled drugs that address the symptoms and respiratory complications of COPD—long-acting beta agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and high-dose inhaled corticosteroids (ICS).1 At the last count there were five LABAs, four LAMAs and four ICS compounds licensed for use in COPD.2 Although this does not sound excessive, there are …